Atlas Trials

An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19

Clinical trial NCT04412018 · COMPLETED

Trial details

NCT number
NCT04412018
Sponsor
Canadian Medical and Surgical Knowledge Translation Research Group
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
COVID-19Inflammatory Response
Start date
2020-06-04
Primary completion
2020-11-06
Enrollment
100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.